Table 2.
Comparison of overall survival for bevacizumab between model, empirical data, and real-world evidence in HRD-positive patients
| 1 year (%) | 2 years (%) | 3 years (%) | 5 years (%) | 7 years (%) | 10 years (%) | AIC | BIC | |
|---|---|---|---|---|---|---|---|---|
| Kaplan–Meier data | 96.9 | 82.9 | 70.4 | – | – | – | – | – |
| Exponential | 90.4 | 81.7 | 73.8 | 66.8 | 60.3 | 49.3 | 325.52 | 328.40 |
| Weibull | 96.2 | 84.2 | 66.2 | 16.6 | 16.0 | 14.5 | 312.58 | 318.35 |
| Gompertz | 95.0 | 84.7 | 65.3 | 36.4 | 9.8 | 0.0 | 316.94 | 322.71 |
| Log-logistic | 96.3 | 83.8 | 66.6 | 37.6 | 21.5 | 16.0 | 311.90 | 317.67 |
| Log-normal (base-case) | 96.5 | 83.3 | 68.2 | 44.2 | 28.9 | 16.2 | 311.02 | 316.78 |
| Generalized gamma | 96.4 | 83.1 | 68.7 | 46.5 | 32.5 | 20.3 | 312.97 | 321.62 |
|
Takaya et al., 2020 [30] (HRD ≥63)a |
92.5 | 84.7 | 73.6 | 46.3 | 33.5 | 22.7 | – | – |
|
Takaya et al., 2020 [30] (HRD 42–62)a |
87.4 | 72.8 | 55.4 | 24.9 | 17.2 | 5.9 | – | – |
| Norquist et al., 2018 [31]a | 99.9 | 90.9 | 76.4 | 53.3 | – | – | – | – |
| Kehoe et al., 2015 [23] | – | – | – | 34 | – | – | – | – |
| Gadducci et al., 2017 [25] | – | 87.1 | – | 41.8 | 32.6 | – | – | |
| Vergote et al., 2018 [27] | 76.8 | 64.4 | 45.8 | 31.1 | – | 11.7 | – | – |
AIC Akaike information criterion, BIC Bayesian information criterion, HRD homologous recombination deficiency
aEstimated using digitization software